Abstract
With any therapy for early prostate cancer, control must be evaluated with a view to toxicities. Brachytherapy may be associated with urethral and rectal toxicity and erectile impotence. Patients with large glands or significant symptoms before treatment are at greatest risk. Long-term toxicity can be minimized by understanding the tolerance of the normal tissues and meticulous placement of the radioactive seeds.
Get full access to this article
View all access options for this article.
